Cargando…
Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients
BACKGROUND: A new approach to the treatment of COPD includes controlling inflammation because of its important role in exacerbation of the disease. Recently, roflumilast has been added as a therapeutic option for COPD. Roflumilast is an oral phosphodiesterase-4 inhibitor that targets inflammatory ce...
Autores principales: | Porpodis, Konstantinos, Domvri, Kalliopi, Zarogoulidis, Paul, Petridis, Dimitrios, Tsirgogianni, Katerina, Papaioannou, Antonis, Hatzizisi, Olga, Kioumis, Ioannis, Liaka, Alexandra, Kikidaki, Violeta, Lampaki, Sofia, Organtzis, John, Zarogoulidis, Konstantinos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4474389/ https://www.ncbi.nlm.nih.gov/pubmed/26109853 http://dx.doi.org/10.2147/COPD.S83205 |
Ejemplares similares
-
Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?
por: Domvri, Kalliopi, et al.
Publicado: (2015) -
Phosphodiesterase (PDE)-4 Inhibitors and COPD Correlation with Cancer
por: Organtzis, John, et al.
Publicado: (2014) -
Potential synergistic effect of phosphodiesterase inhibitors with chemotherapy in lung cancer
por: Domvri, Kalliopi, et al.
Publicado: (2017) -
Cytokine gene polymorphisms in Greek patients with severe asthma
por: Papakosta, Despina, et al.
Publicado: (2015) -
Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment
por: Pitsiou, Georgia, et al.
Publicado: (2014)